Target intelligence / Profile preview

FAS antisense RNA 1 (FAS-AS1)

Target
FAS-AS1
Molecular classification
Long non-coding RNA (lncRNA), Natural antisense transcript (NAT), Non-coding RNA
01

Overview

FAS antisense RNA 1 (FAS-AS1) is a long non-coding RNA transcribed from the opposite strand of intron 1 of the human FAS gene on chromosome 10. It functions as a natural antisense transcript that regulates alternative splicing and expression of FAS gene isoforms, most notably by inhibiting RBM5-mediated exon 6 skipping, which in turn modulates production of the apoptotic sFas protein. FAS-AS1 regulation is implicated in the control of apoptosis and is relevant in various diseases, including certain lymphomas and autoimmune conditions. FAS-AS1 does not encode a protein and is not considered a conventional therapeutic target such as a receptor or enzyme, but its regulatory role in cell death pathways makes it of interest in pathogenesis and potential biomarker research

Other names
FAS-ASFASASSAF
02

Mechanism of action

Not directly drug-targeted, but biological regulation involves: Epigenetic silencing via EZH2-mediated promoter methylation; Modulation of RBM5-mediated exon skipping in Fas pre-mRNA, altering sFas production and thereby apoptosis sensitivity

03

Biological functions

Regulation of gene expression (specifically regulation of FAS gene isoforms)Modulation of alternative splicing (notably influences Fas alternative splicing via interaction with RBM5)Regulation of apoptosis (by influencing FAS-mediated apoptotic pathways)
04

Disease associations

Cancer (notably lymphomas, implicated in alternative splicing and apoptosis modulation)Autoimmune disease (discoid lupus erythematosus)Osteoarthritis
05

Safety considerations

Therapeutic modulation of lncRNAs such as FAS-AS1 may carry risks typical of RNA-targeting therapies (off-target effects, delivery challenges, unknown long-term safety)Indirect targeting by drugs that affect its expression (e.g., EZH2 inhibitors) may affect cell survival and apoptosis, potentially leading to cytotoxicity or immune modulation
06

Interacting drugs

EZH2 inhibitors (e.g., DZNeP/3-Deazaneplanocin A)

1 more in the full profile.

07

Biomarkers

FAS-AS1 expression levels may serve as a biomarker for apoptosis modulation and potentially for response to agents that modulate Fas signaling or EZH2 activity

Beyond the preview

Go deeper on FAS antisense RNA 1 (FAS-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FAS antisense RNA 1 (FAS-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call